Correspondence 0000950170-23-053105 from Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE)
Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: Oct. 12, 2023 · CIK: 0001444192 · Accession: 0000950170-23-053105
AI Filing Summary & Sentiment
File numbers found in text: 333-274899
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Registration Statement on Form S-3 Filed October 6, 2023 File No. 333-274899 Request for Acceleration of Effective Date
Dear Mr. Gorsky:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on October 16, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Brandon Kinnard of Hogan Lovells US LLP at (303) 454-2477. Also, please notify Mr. Kinnard when this request for acceleration has been granted.
Very truly yours,
ACASTI PHARMA INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ACASTI PHARMA INC. 2572 boul. Daniel-Johnson. 2nd Floor Laval, Québec, Canada H7T 2R3 October 12, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Acasti Pharma Inc. Registration Statement on Form S-3 Filed October 6, 2023 File No. 333-274899 Request for Acceleration of Effective Date Dear Mr. Gorsky: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on October 16, 2023, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Brandon Kinnard of Hogan Lovells US LLP at (303) 454-2477. Also, please notify Mr. Kinnard when this request for acceleration has been granted. Very truly yours, ACASTI PHARMA INC. By: /s/ Prashant Kohli Name: Prashant Kohli Title: Chief Executive Officer MACROBUTTON DocID \\4133-8110-5740 v1